|
Thrombophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plasminogen-fibrin interactions are altered in young and middle-aged VTE patients, without known thrombophilias, except increased factor VIII.
|
29324332 |
2018 |
|
Thrombophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Other biomarkers reviewed, which did not consistently demonstrate significant associations with VTE included prothrombin fragments F1 + 2, factor VIII, protein C, protein S, von Willebrand antigen and activity, antithrombin, thrombin antithrombin complex, antiphospholopid antibody, plasminogen activator inhibitor, tissue factor pathway inhibitor and several variants associated with known hypercoagulable states (factor V Leiden, prothrombin gene variant, methylenetetrahydrofolate reductase variant).
|
29407626 |
2018 |
|
Thrombophilia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Normal pregnancy is a state of hypercoagulability with diminishing fibrinolytic activity, which is mainly caused by an increase of plasminogen activator inhibitor type 1 (PAI-1).
|
28758928 |
2017 |
|
Thrombophilia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study assessed gene mutations (factor V Leiden, prothrombin G20210A, plasminogen activator inhibitor, methylenetetrahydrofolate reductase) and serologic thrombophilias (high levels of factors VIII and XI, homocysteine, anticardiolipin immunoglobulin G and immunoglobulin M antibodies, and lupus anticoagulant; low antigenic protein C, S, and free S; and antithrombin III deficiency).
|
27459142 |
2016 |
|
Thrombophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hereditary protein C (PC) deficiency and congenital plasminogen (PLG) deficiency are both factors of thrombophilia which were caused by PC and PLG gene mutations with the characteristics of activity and antigen decreasing inconsonantly.
|
27314862 |
2016 |
|
Thrombophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
To identify inherited factors: Protein C (PC), protein S (PS), antithrombin (AT), plasminogen (Plg), the activated PC resistance (APCR), prothrombin (PT) mutation G20210 A (PTG20210 A) and methylenetetrahydrofolate reductase C677 T polymorphism (MTHFR C677 T), as well as acquired-risk factors such as: diabetes mellitus, surgeries, smoking, obesity, hypertension, trauma, alcoholism, family history; and their association, in Mexican patients with diagnostic of thrombophilia.
|
26315791 |
2015 |
|
Thrombophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Elevated plasminogen activator inhibitor type-1 (PAI-1) as contributing factor in pathogenesis of hypercoagulable state in antiphospholipid syndrome.
|
23519427 |
2013 |
|
Thrombophilia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
After returning to Korea he was tested for thrombophilia which revealed decreased activity of plasminogen and subsequent analysis of PLG gene showed heterozygous Ala620Thr mutation.
|
23772166 |
2013 |
|
Thrombophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Laboratory work up showed elevated D-dimers and antithrombin levels <20% (lowest 15%), age-related values for protein C, protein S, plasminogen, and no other inherited thrombophilia.
|
22961244 |
2012 |
|
Thrombophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, this mini-review aims to address a comprehensive summary of thrombophilias and thrombosis, and discuss the role of polymorphisms in Factor V (FV Leiden), Prothrombin, Plasminogen activator inhibitor type-1 (PAI-1), Methylenetetrahydrofolate reductase (MTHFR) and Cystathionine β-synthase (CBS) genes as risk factors for thrombophilias.
|
22512572 |
2012 |
|
Thrombophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Elevated plasma concentrations of plasminogen activator inhibitor type 1 (PAI-1), also named serpin E1, are encountered in patients with thrombophilia, atherosclerosis, septicemia and the metabolic syndrome and may be associated with an increased risk of complications.
|
19132219 |
2008 |
|
Thrombophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We carried out serologic measures of thrombophilia (homocysteine, anticardiolipin antibodies [ACLA] immunoglobulin G and immunoglobulin M, lupus anticoagulant, factor VIII, factor XI, protein C, total and free protein S, antithrombin III) and hypofibrinolysis (plasminogen activator inhibitor activity [PAI-Fx], lipoprotein[a]).
|
16154434 |
2005 |
|
Thrombophilia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
After confirming clinically suspected thromboembolism with suitable imaging methods, pediatric patients should be screened for common gene mutations (factor V G1691A, prothrombin G20210A and MTHFR C677T genotypes), rare genetic deficiencies (protein C, protein S, antithrombin, and plasminogen), and new candidates for genetic thrombophilia causing elevated levels of lipoprotein(a), and homocysteine, and probable genetic risk factors (elevations in fibrinogen, factor IX, and factor VIIIC, and decreases in factor XII).
|
12172465 |
2002 |
|
Thrombophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Smoking and impaired plasminogen activation with hypercoagulation and fibrinolysis inhibition have been proposed as having a role in predisposition to these diseases.
|
12140748 |
2002 |
|
Thrombophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mean concentrations of plasminogen activator inhibitor, apolipoproteins, lipid metabolism parameters, and indicators of thrombophilia did not differ in both groups.
|
11953626 |
2002 |
|
Thrombophilia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found that rAN II enhanced plasmin generation on vascular endothelium in vitro and reduced thrombus formation in vivo, and concluded that enhancement of endothelial fibrinolytic activity by annexin II could modulate the hypercoagulable state of atherosclerosis.
|
11739291 |
2001 |
|
Thrombophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Single defects comprised established causes of inherited thrombophilia: FV:Q506 (homozygous n = 10, heterozygous n = 69), protein C (homozygous n = 1; heterozygous n = 31), heterozygous type I deficiency states of protein S (n = 7), antithrombin (n = 7) and homocystinuria (n = 6); potentially inherited clotting abnormalities which may be associated with thrombophilia: F.XII (n = 3), plasminogen (n = 2), HCII (n = 1), increased HRGP (n = 4); new candidate risk factors for thrombophilia: elevated plasma levels of Lp(a) (n = 26), F.II (n = 1).
|
10650845 |
1999 |
|
Thrombophilia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
However, a screening hypercoagulation profile indicated low functional levels of plasminogen activity.
|
1962336 |
1991 |
|
Thrombophilia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
At present, different congenital defects in several proteins--antithrombin III (AT III), protein C (PC), protein S (PS), and plasminogen (PLG)--are known to be causes of hereditary predisposition to thrombosis (thrombophilia).
|
1826407 |
1991 |
|
Thrombophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Elevated plasminogen activator inhibitor (PAI), a cause of thrombophilia? A study in 203 patients with familial or sporadic venous thrombophilia.
|
2683188 |
1989 |
|
Thrombophilia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Abnormal plasminogen: a genetically determined cause of hypercoagulability.
|
6208389 |
1984 |